BMY Bristol-Myers Squibb Company NYSE · Healthcare · USD Watching
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for… Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Price history
Loading price data…
Recent news
The Engine Behind ABBV Stock Has Real Parts
Trefis ·
Should You Buy, Hold, or Sell BMY Stock Ahead of Q2 Earnings?
Zacks ·
How Immunocore Is Expanding Beyond Its Rare-Cancer Drug Kimmtrak
Zacks ·
Is Immunocore Stock Attractive After Kimmtrak's Strong Sales Growth?
Zacks ·
Immunocore's Kimmtrak Growth Story and Major 2026 Catalysts Ahead
Zacks ·
Wall Street's Insights Into Key Metrics Ahead of Bristol Myers (BMY) Q2 Earnings
Zacks ·
Israel "Izzy" Englander Increased His Position in This Pharma Stock by 780%. Does He Know Something Wall Street Doesn't?
Motley Fool ·
Why Agilent Technologies (A) Is Up 5.4% After New FDA Nod For OPDIVO Cancer Test
Simply Wall St. ·
Details
IndustryDrug Manufacturers - General
ExchangeNYSE
CurrencyUSD
Next-day prediction
↑ Up buy

4% confidence

2-day prediction
↑ Up

25% confidence

Technical signals

Price & volume indicators the model reads, as of 2026-07-27. These are computed from recent trading — momentum, trend, volatility and volume — and feed the prediction above.

Momentum
RSI (14) 0.658
Stochastic %K (14) 0.868
Stochastic %D (14) 0.871
Stochastic RSI (14) 1.000
Trend
Price vs SMA (20) 0.060
Price vs EMA (26) 0.062
Price vs WMA (20) 0.043
PPO (12/26/9) 0.025
Volatility
Bollinger %B (20/2) 0.957
Bollinger Bandwidth (20/2) 0.131
ATR % (14) 0.024
Keltner position (20/10/2) 1.021
Volume
OBV change (20) 0.204
Money Flow Index (14) 0.703
Chaikin Money Flow (20) 0.004
Money Flow Multiplier -0.443
Returns & Statistics
Return (1) 0.007
Return (2) 0.017
Overnight gap 0.005
Intraday range 0.019

Technical indicators — BMY

These price/volume technical indicators are computed from recent trading and are part of what the prediction model reads for BMY. Values are as of 2026-07-27 (coverage 100% — the share of indicators with enough price history to compute). A value of 0 with low coverage usually means "not enough history yet", not a true reading.

Momentum

Oscillators that gauge how strongly and how fast the price has been moving — used to spot overbought/oversold conditions and shifts in drive.

RSI (7)
Relative Strength Index: 0–1 scale of recent gains vs losses. Above ~0.7 is 'overbought' (may be due to cool off); below ~0.3 'oversold'.
 0.7378
RSI (14)
Relative Strength Index: 0–1 scale of recent gains vs losses. Above ~0.7 is 'overbought' (may be due to cool off); below ~0.3 'oversold'.
 0.6580
RSI (21)
Relative Strength Index: 0–1 scale of recent gains vs losses. Above ~0.7 is 'overbought' (may be due to cool off); below ~0.3 'oversold'.
 0.6204
Stochastic %K (14)
Where the close sits within its recent high–low range (0 = at the low, 1 = at the high).
 0.8679
Stochastic %D (14)
A 3-day smoothing of Stochastic %K — the slower signal line.
 0.8708
Stochastic %K (9)
Where the close sits within its recent high–low range (0 = at the low, 1 = at the high).
 0.8625
Stochastic %D (9)
A 3-day smoothing of Stochastic %K — the slower signal line.
 0.8667
Stochastic RSI (14)
RSI rescaled to where it sits in its own recent range (0–1) — a more sensitive overbought/oversold reading.
 1.0000
Williams %R (14)
Like the Stochastic, the close's position in the recent range (0 = low, 1 = high).
 0.8679
CCI (20)
Commodity Channel Index: how far price is from its average, squashed to about −1…+1. High = unusually strong, low = unusually weak.
 0.8938
CCI (40)
Commodity Channel Index: how far price is from its average, squashed to about −1…+1. High = unusually strong, low = unusually weak.
 0.9590
Rate of Change (5)
Log return over the lookback — simple momentum (positive = up).
 0.0391
Rate of Change (10)
Log return over the lookback — simple momentum (positive = up).
 0.0528
Rate of Change (20)
Log return over the lookback — simple momentum (positive = up).
 0.0952
KDJ %K (9)
Smoothed position of the close in its recent range (0–1).
 0.8255
KDJ %D (9)
A further smoothing of KDJ %K.
 0.7865
KDJ %J (9)
The fast, sensitive leg of KDJ — exaggerates turns.
 0.7180
Ultimate Oscillator (7/14/28)
Buying pressure blended across short, medium and long windows (0–1).
 0.4501
True Strength Index (25/13)
Double-smoothed momentum, about −1…+1 (positive = upward drive).
 0.2130

Trend

Moving-average and directional measures of which way the price is trending and how strong that trend is.

Price vs SMA (10)
How far the close is above (+) or below (−) its simple moving average, as a fraction.
 0.0342
Price vs SMA (20)
How far the close is above (+) or below (−) its simple moving average, as a fraction.
 0.0596
Price vs SMA (50)
How far the close is above (+) or below (−) its simple moving average, as a fraction.
 0.0946
Price vs SMA (100)
How far the close is above (+) or below (−) its simple moving average, as a fraction.
 0.0883
Price vs SMA (200)
How far the close is above (+) or below (−) its simple moving average, as a fraction.
 0.1560
Price vs EMA (12)
How far the close is above/below its exponential moving average (weights recent prices more).
 0.0358
Price vs EMA (26)
How far the close is above/below its exponential moving average (weights recent prices more).
 0.0620
Price vs EMA (50)
How far the close is above/below its exponential moving average (weights recent prices more).
 0.0797
Price vs EMA (200)
How far the close is above/below its exponential moving average (weights recent prices more).
 0.1610
Price vs WMA (20)
How far the close is above/below its weighted moving average.
 0.0429
PPO (12/26/9)
Percentage Price Oscillator — MACD expressed as a percent so it compares across stocks. Positive = short-term momentum above long-term.
 0.0253
PPO Signal (12/26/9)
The smoothed signal line of the PPO.
 0.0192
PPO Histogram (12/26/9)
PPO minus its signal line — momentum of the momentum.
 0.0061
ADX (14)
Trend strength on a 0–1 scale (direction-agnostic). Higher = a stronger trend.
 0.2711
+DI (14)
Strength of upward directional movement (0–1).
 0.3217
−DI (14)
Strength of downward directional movement (0–1).
 0.1106
Aroon Up (25)
How recently a new high was made (1 = just now).
 1.0000
Aroon Down (25)
How recently a new low was made (1 = just now).
 0.0000
Aroon Oscillator (25)
Aroon Up minus Down — positive favours an uptrend.
 1.0000
Parabolic SAR distance
How far price is from the trailing stop-and-reverse level, as a fraction of price.
 0.0337
Parabolic SAR side
+1 when price is above the SAR (uptrend), −1 below.
 1.0000
Vortex +VI (14)
Strength of upward trend movement (centred at 0).
 0.2013
Vortex −VI (14)
Strength of downward trend movement (centred at 0).
 -0.2580
Vortex difference (14)
+VI minus −VI — positive favours an uptrend.
 0.4594
MA slope (50/20)
The recent slope of a moving average (positive = rising trend).
 0.0125

Volatility

How much the price is swinging around — wide bands and high readings mean larger, riskier moves.

Bollinger %B (20/2)
Where price sits within its Bollinger Bands (0 = lower band, 1 = upper). Above 1 or below 0 is an extended move.
 0.9567
Bollinger Bandwidth (20/2)
How wide the bands are relative to price — bigger means more volatile.
 0.1305
ATR % (14)
Average True Range as a percent of price — typical daily swing size.
 0.0241
Keltner position (20/10/2)
Where price sits within its Keltner Channel (0–1).
 1.0206
Keltner width (20/10/2)
Width of the Keltner Channel relative to price.
 0.1019
Donchian position (20)
Where price sits within its recent high–low channel (0–1).
 0.9677
Donchian width (20)
Width of the recent high–low channel relative to price.
 0.1367
Realized volatility (10)
Standard deviation of recent daily returns — how jumpy the stock has been.
 0.0206
Realized volatility (20)
Standard deviation of recent daily returns — how jumpy the stock has been.
 0.0211
Realized volatility (60)
Standard deviation of recent daily returns — how jumpy the stock has been.
 0.0197
Chaikin Volatility (10/10)
Whether the daily high–low range is expanding (+) or contracting (−).
 0.0647
Ulcer Index (14)
A drawdown-based stress measure — higher means deeper/longer dips from recent highs.
 5.2047

Volume

Whether trading activity is confirming the price move — money flowing in or out, and unusually heavy or light volume.

OBV change (20)
On-Balance Volume trend — net volume flowing in (+) or out (−).
 0.2041
Money Flow Index (14)
A volume-weighted RSI (0–1). High = strong buying pressure.
 0.7028
Chaikin Money Flow (20)
Buying vs selling pressure weighted by volume (−1…+1).
 0.0044
Money Flow Multiplier
Where the close finished in the bar's range, the building block of accumulation/distribution (−1…+1).
 -0.4426
Accum/Dist change (20)
Recent change in the Accumulation/Distribution line (buying vs selling pressure).
 0.0044
Price vs VWAP (20)
How far the close is above/below the rolling volume-weighted average price.
 0.0611
Force Index (13)
Return times relative volume — the push behind a move.
 0.0075
Ease of Movement (sign) (14)
+1 when price rose easily on light volume, −1 when it fell easily.
 1.0000
Ease of Movement (z) (14)
How unusual today's ease-of-movement is vs recent days.
 0.1451
Volume Rate of Change (14)
Log change in volume vs n days ago — a volume surge/lull.
 0.0264
Volume Rate of Change (25)
Log change in volume vs n days ago — a volume surge/lull.
 -1.1225
Relative Volume (z) (20)
How many standard deviations today's volume is above/below its recent average.
 -0.1877
Relative Volume (z) (50)
How many standard deviations today's volume is above/below its recent average.
 -0.3112
Relative Volume (20)
Today's volume vs its recent average (log scale; >0 = above).
 -0.0641
Relative Volume (50)
Today's volume vs its recent average (log scale; >0 = above).
 -0.1416

Returns & Statistics

Recent returns over several horizons plus statistical shape (skew, fat tails, drawdown, risk-adjusted return).

Return (1)
Log return over the horizon (positive = up).
 0.0075
Return (2)
Log return over the horizon (positive = up).
 0.0169
Return (3)
Log return over the horizon (positive = up).
 0.0292
Return (5)
Log return over the horizon (positive = up).
 0.0391
Return (10)
Log return over the horizon (positive = up).
 0.0528
Return (20)
Log return over the horizon (positive = up).
 0.0952
Overnight gap
Open vs the prior close — overnight move.
 0.0050
Intraday range
High minus low as a fraction of price — the day's swing.
 0.0195
True range
True range (gap-aware swing) as a fraction of price.
 0.0216
Return skew (20)
Asymmetry of recent returns — negative means crash-prone tails.
 -0.3105
Return skew (60)
Asymmetry of recent returns — negative means crash-prone tails.
 0.0631
Return kurtosis (20)
Fat-tailedness of recent returns — high means jumpy/extreme moves.
 -0.2849
Return kurtosis (60)
Fat-tailedness of recent returns — high means jumpy/extreme moves.
 0.0787
Downside deviation (20)
Volatility of only the negative returns — pure downside risk.
 0.0126
Downside deviation (60)
Volatility of only the negative returns — pure downside risk.
 0.0128
Max drawdown (20)
Largest peak-to-trough drop over the window, as a fraction.
 0.0403
Max drawdown (60)
Largest peak-to-trough drop over the window, as a fraction.
 0.1088
Return/risk (20)
Average return divided by its volatility — recent risk-adjusted return.
 0.2254
Return/risk (60)
Average return divided by its volatility — recent risk-adjusted return.
 0.0795
Return persistence (20)
Whether up days tend to follow up days (+) or reverse (−).
 -0.5511
Return persistence (60)
Whether up days tend to follow up days (+) or reverse (−).
 -0.2136
Price z-score (20)
How many standard deviations the price is from its recent average.
 1.7806
Price z-score (50)
How many standard deviations the price is from its recent average.
 2.3864
Return z-score (20)
How unusual the latest return is vs recent returns.
 0.1316
Return z-score (50)
How unusual the latest return is vs recent returns.
 0.2732
Company locations
Site City, country Conf.
Bristol-Myers Squibb Company — GLEIF legal address GLEIF legal, United States 72%
Bristol-Myers Squibb Company — Wikidata HQ New York City, United States 78%
Latest signals
Loading signals…